• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply.

作者信息

Kim Gi-Ae, Lim Young-Suk

机构信息

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Republic of Korea.

出版信息

Aliment Pharmacol Ther. 2020 Aug;52(3):576-577. doi: 10.1111/apt.15881.

DOI:10.1111/apt.15881
PMID:32656844
Abstract
摘要

相似文献

1
Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply.
Aliment Pharmacol Ther. 2020 Aug;52(3):576-577. doi: 10.1111/apt.15881.
2
Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B-authors' reply.信函：慢性乙型肝炎患者血清乙肝病毒DNA与肝细胞癌风险——作者回复
Aliment Pharmacol Ther. 2021 Mar;53(6):763. doi: 10.1111/apt.16278.
3
Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Authors' reply.信函：高病毒载量且谷丙转氨酶无显著升高的未经治疗的HBeAg阴性慢性乙型肝炎患者发生肝细胞癌的风险。作者回复
Aliment Pharmacol Ther. 2019 Sep;50(5):619-620. doi: 10.1111/apt.15451.
4
Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply.
Aliment Pharmacol Ther. 2020 Jun;51(12):1440-1441. doi: 10.1111/apt.15794.
5
Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients.信函：仅中度水平的血清乙型肝炎病毒DNA与慢性乙型肝炎患者肝细胞癌风险增加无关。
Aliment Pharmacol Ther. 2020 Aug;52(3):575-576. doi: 10.1111/apt.15829.
6
Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma - authors' reply.信函：乙肝表面血清学清除确实降低肝细胞癌风险——作者回复
Aliment Pharmacol Ther. 2016 Sep;44(6):650-1. doi: 10.1111/apt.13730.
7
Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance - authors' reply.
Aliment Pharmacol Ther. 2017 May;45(9):1288-1289. doi: 10.1111/apt.14026.
8
Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Authors' reply.
Aliment Pharmacol Ther. 2016 Oct;44(8):910. doi: 10.1111/apt.13778.
9
Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.信函：慢性乙型肝炎患者血清乙肝病毒DNA与肝细胞癌风险
Aliment Pharmacol Ther. 2021 Mar;53(6):761-762. doi: 10.1111/apt.16264.
10
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply.信函：慢性乙型肝炎免疫耐受期肝细胞癌的风险——作者回复
Aliment Pharmacol Ther. 2020 Sep;52(5):913-914. doi: 10.1111/apt.15992.